Drug discovery and development – Page 25
-
-
-
OpinionHow much does fashion influence chemists?
Is that new reaction the next Nobel-worthy breakthrough, or just a flash in the pan?
-
OpinionRestarting the mental health pipeline
The lack of UK investment in new drugs for mental health disorders is a problem – but the tide may be about to turn
-
CareersThe trials and tribulations of drug discovery
The many pitfalls medicinal chemists face when creating a new drug
-
ResearchDibrominated tag helps identify new natural products
New substance allows researchers to find new aldehyde- and ketone-containing natural products
-
OpinionRegulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
-
OpinionPutting chemistry back in biology
The chemical nature of biomolecular interactions can no longer be ignored
-
BusinessLilly to buy Boehringer’s pet vaccines
Deal strengthens Lilly’s animal medicine division following recent acquisition
-
FeatureDrugging the epigenome
Drugs that change how your genes are switched on or off could change how we treat many diseases, as Rachel Brazil discovers
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
ResearchFreeze-dried cell parts for hassle-free molecule manufacturing
‘Just add water’ reaction pellets allow drugs and vaccines to be produced without special equipment or training
-
OpinionSlimmer synthesis
Atom economy is a noble aim, but there are other routes to efficient molecule making
-
BusinessFDA’s first Duchenne drug approval reveals schism
Oligonucleotide drug reaches market amid pressure from patient families and strife over ‘patient-focused drug development’ at the regulator
-
ResearchSynthesis strategy takes the pain out of finding malaria drugs
Compound libraries could help find treatments for a whole host of diseases
-
BusinessJoined-up thinking
The rift between contract medicinal chemistry and chemical development needs to be bridged
-
OpinionDon’t fear the Crispr
Does simple gene-editing mean the end of traditional medicinal chemistry? Probably not
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
OpinionHow to solve global health inequality
Our skills as scientists hold the answer, says the Bill & Melinda Gates Foundation
-
OpinionPreparing for the future of pharma
Dave Allen discusses how scenario planning helps to define uncertainty in pharma